Low-intensity focused ultrasound for cocaine use disorder: High resolution targeting of the human insula
低强度聚焦超声治疗可卡因使用障碍:人类脑岛的高分辨率靶向
基本信息
- 批准号:10669693
- 负责人:
- 金额:$ 59.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-01 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AbstinenceAddictive BehaviorAdoptionAffectAnatomyAnimal ModelAnteriorAreaBehavioralBrainBrain regionCessation of lifeChronicClinicalCocaineCocaine DependenceCocaine use disorderCuesDataDecision MakingDiseaseDorsalDoseEmotionalFDA approvedFocused UltrasoundFutureGoalsHumanIndividualInsula of ReilInterventionLateralLesionLongevityMagnetic Resonance ImagingMaintenanceMeasuresMethodsModelingNeurologicNeurosurgical ProceduresPatient Self-ReportPatientsPharmaceutical PreparationsPharmacotherapyPhasePhysiologicalPopulationPredispositionRelapseResolutionSafetySensorySocietiesSpottingsStimulusSubstance Use DisorderTechniquesTechnologyTemporal LobeTherapeuticTherapeutic EffectTreatment EfficacyUltrasonic TherapyUnited States Food and Drug AdministrationVisceraladdictionblood oxygen level dependentbrain dysfunctioncatalystclinical effectcocaine cravingcocaine cuecocaine exposurecocaine seekingcocaine usecostcraniumcravingcue reactivitydirected attentionexperienceimprovedinnovationmillimetermultimodal dataneurobehavioralneuroregulationnoninvasive brain stimulationnovel therapeutic interventionrepairedresponsesafety assessmentsafety testingsmoking cessationstemtransmission processultrasound
项目摘要
ABSTRACT
Cocaine use disorder (CUD) is a chronic relapsing disorder with significant burden to society costing more than
$85 billion per year globally and there is no US Food and Drug Administration-approved intervention. There is a
critical need to develop effective new treatment strategies. One rapidly emerging potential therapeutic is
neuromodulation using low-intensity focused ultrasound (LIFU). The enormous potential of LIFU stems from the
ability to focus ultrasound through the intact skull to a millimeter-sized focal spot size anywhere in the brain. This
makes it a powerful alternative to both invasive neurosurgical procedures and other noninvasive brain stimulation
techniques that have limited spatial resolution and can only reach superficial areas of the brain. One promising
target to treat cocaine use disorder (CUD) is the dorsal anterior insular cortex (dAI). Unfortunately, the dAI lies
deep within the lateral sulcus covered by the overlying opercula of the temporal lobe and is not accessible with
conventional noninvasive neuromodulatory techniques. As such, LIFU provides a potentially transformative
methods to non-invasively modulate the dAI to reduce cocaine craving and addiction. The dAI is a critical brain
region which is activated in the response to drug cue exposure and its extent of activation is positively correlated
with self-reported craving in human studies. In small animal models, reversible inactivation of dorsal anterior
insula reduces cocaine seeking, decreases relapse after voluntary abstinence and decreases cue-induced and
context-induced reinstatement of cocaine seeking. Remarkably, humans with damage to the insula were able to
stop smoking easily and without experiencing cravings or relapse. In addition, the dAI is part of the salience
network (SN). The SN is implicated in the direction of attention toward important stimuli and integration of top-
down appraisal and bottom-up visceral and sensory information. Models posit the dAI first assesses the
emotional value of incoming stimuli before transmitting the information to other nodes to plan and initiate future
goal directed actions. In addiction this network is dysfunctional leading to a disproportionate saliency and
sensitivity to drug related cues that biases decision making to use and ultimately abuse.
To advance LIFU as a potential therapeutic for the treatment of CUD, in the UG3 phase of this proposal we will
first test the safety and tolerability of the intervention and examine how selective inhibition of dAI reduces its
activity to affect cue-induced craving. Develop. Upon successful completion of the UG3 phase, the UH3 phase
will build upon these findings by examining the effect of dose and the duration of effect as well as how LIFU to
dAI affects whole-brain network dynamics as how this affects craving for cocaine. The application of this
information will provide a fundamental break-through in understanding how ultrasound energy can be rationally
deployed to produce predictable clinical effects and act as a catalyst for the widespread clinical adoption of this
technology for the treatment of CUD as well as other forms of substance use disorder.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NASSIMA AIT-DAOUD其他文献
NASSIMA AIT-DAOUD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NASSIMA AIT-DAOUD', 18)}}的其他基金
1/2-Pharmacogenetic Treatments for Alcoholism
1/2-酒精中毒的药物遗传学治疗
- 批准号:
8273389 - 财政年份:2012
- 资助金额:
$ 59.48万 - 项目类别:
1/2-Pharmacogenetic Treatments for Alcoholism
1/2-酒精中毒的药物遗传学治疗
- 批准号:
8460484 - 财政年份:2012
- 资助金额:
$ 59.48万 - 项目类别:
New Pharmacotherapy for Alcohol and Co-morbid Disorders
酒精和共病疾病的新药物疗法
- 批准号:
8318743 - 财政年份:2010
- 资助金额:
$ 59.48万 - 项目类别:
New Pharmacotherapy for Alcohol and Co-morbid Disorders
酒精和共病疾病的新药物疗法
- 批准号:
8520114 - 财政年份:2010
- 资助金额:
$ 59.48万 - 项目类别:
New Pharmacotherapy for Alcohol and Co-morbid Disorders
酒精和共病疾病的新药物疗法
- 批准号:
8139054 - 财政年份:2010
- 资助金额:
$ 59.48万 - 项目类别:
New Pharmacotherapy for Alcohol and Co-morbid Disorders
酒精和共病疾病的新药物疗法
- 批准号:
7949511 - 财政年份:2010
- 资助金额:
$ 59.48万 - 项目类别:
New Medication Treatments for Stimulant Dependence
治疗兴奋剂依赖的新药物治疗
- 批准号:
8013349 - 财政年份:2007
- 资助金额:
$ 59.48万 - 项目类别:
New Medication Treatments for Stimulant Dependence
治疗兴奋剂依赖的新药物治疗
- 批准号:
7313772 - 财政年份:2007
- 资助金额:
$ 59.48万 - 项目类别:
New Medication Treatments for Stimulant Dependence
治疗兴奋剂依赖的新药物治疗
- 批准号:
8210949 - 财政年份:2007
- 资助金额:
$ 59.48万 - 项目类别:
New Medication Treatments for Stimulant Dependence
治疗兴奋剂依赖的新药物治疗
- 批准号:
7751305 - 财政年份:2007
- 资助金额:
$ 59.48万 - 项目类别:
相似海外基金
Neuronal regulation of glutamate homeostasis in addictive behavior
成瘾行为中谷氨酸稳态的神经元调节
- 批准号:
364631096 - 财政年份:2017
- 资助金额:
$ 59.48万 - 项目类别:
Research Fellowships
The Effects of Sadness Versus Gratitude on Economic Decision Making and Addictive Behavior
悲伤与感恩对经济决策和成瘾行为的影响
- 批准号:
1559511 - 财政年份:2016
- 资助金额:
$ 59.48万 - 项目类别:
Continuing Grant
Beta-arrestin Regulation of Ghrelin Signaling in Modulating Addictive Behavior
β-抑制素对 Ghrelin 信号传导在调节成瘾行为中的调节
- 批准号:
8811411 - 财政年份:2014
- 资助金额:
$ 59.48万 - 项目类别:
Beta-arrestin Regulation of Ghrelin Signaling in Modulating Addictive Behavior
β-抑制素对 Ghrelin 信号传导在调节成瘾行为中的调节
- 批准号:
8637290 - 财政年份:2014
- 资助金额:
$ 59.48万 - 项目类别:
Orexin and Leptin Regulation of Feeding and Addictive Behavior in the VTA
食欲素和瘦素对 VTA 中进食和成瘾行为的调节
- 批准号:
8236865 - 财政年份:2011
- 资助金额:
$ 59.48万 - 项目类别:
Orexin and Leptin Regulation of Feeding and Addictive Behavior in the VTA
食欲素和瘦素对 VTA 中进食和成瘾行为的调节
- 批准号:
8434870 - 财政年份:2011
- 资助金额:
$ 59.48万 - 项目类别:
Orexin and Leptin Regulation of Feeding and Addictive Behavior in the VTA
食欲素和瘦素对 VTA 中进食和成瘾行为的调节
- 批准号:
8215386 - 财政年份:2011
- 资助金额:
$ 59.48万 - 项目类别:
Orexin and Leptin Regulation of Feeding and Addictive Behavior in the VTA
食欲素和瘦素对 VTA 中进食和成瘾行为的调节
- 批准号:
7739920 - 财政年份:2009
- 资助金额:
$ 59.48万 - 项目类别:
CBP Acetyltransferase Function in Addictive Behavior
CBP 乙酰转移酶在成瘾行为中的作用
- 批准号:
7173929 - 财政年份:2006
- 资助金额:
$ 59.48万 - 项目类别:
CBP Acetyltransferase Function in Addictive Behavior
CBP 乙酰转移酶在成瘾行为中的作用
- 批准号:
7290942 - 财政年份:2006
- 资助金额:
$ 59.48万 - 项目类别:














{{item.name}}会员




